| Literature DB >> 25114705 |
Abstract
Objective. To evaluate the synergistic analgesic effect of essential oil of Zanthoxylum schinifolium Sieb. et Zucc. (EOZ) and verapamil (Ver). Method. The qualitative and quantitative composition of EOZ were determined with gas chromatography/Mass spectrometer. The interaction between EOZ and Ver in antinociceptive activity was evaluated by using acetic acid-induced writhing, hot plate, and tail flick tests in mice and in isolated toad sciatic nerve test. Results. Linalool, limonene, and sabinene are the major components of EOZ. EOZ (middle-dose: 40 mg·kg(-1), high-dose: 80 mg·kg(-1)) and EOZ + Ver (Each dose group) have remarkable analgesic effects on pain in mice induced by acetic acid-induced writhing, hot plate, and tail flick tests. Low-dose EOZ (20 mg·kg(-1)) had no analgesic action, but when it is combined with Ver it has shown significant antinociception. Verapamil has a faint analgesic effect but was not able to inhibit action potential transmission in toad sciatic nerve. EOZ (0.2%) and EOZ + Ver (0.2% + 0.05%) also inhibited action potential transmission in toad sciatic nerve. Combination of EOZ with Ver had a greater analgesic effect and inhibition of nerve action potential transmission compared to its components EOZ and Ver. Conclusion. The combination of EOZ with Ver produces a synergistic analgesic effect.Entities:
Year: 2014 PMID: 25114705 PMCID: PMC4119645 DOI: 10.1155/2014/505876
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Main constituents of essential oil from Zanthoxylum schinifolium Sieb. et Zucc. determined by GS-MS.
| Retention (min) | Compound name | Relative content (%) |
|---|---|---|
| 7.356 | .alpha.-Pinene | 1.03 |
| 8.475 | .beta.-Phellandrene | 1.26 |
| 8.856 | Sabinene | 9.16 |
| 9.157 | .beta.-Myrcene | 3.87 |
| 9.835 | .alpha.-Terpinene | 1.05 |
| 10.158 | Eucalyptol | 1.64 |
| 10.262 | d-Limonene | 15.34 |
| 10.751 | 1,8-Cineole | 1.05 |
| 11.122 | .gamma.-Terpinene | 1.02 |
| 12.671 | Cis-sabinene hydrate | 1.18 |
| 12.304 | Linalool | 32.54 |
| 13.154 | Linalyl acetate | 1.06 |
| 14.796 | Terpineol | 2.56 |
| 19.255 | 4-Terpinenol | 1.78 |
| 22.038 | .alpha.-Caryophyllene | 1.41 |
| 22.847 | Germacrene | 1.32 |
| 23.469 | .gamma.-Cadinene | 1.03 |
| Different compounds | Trace (<1%) |
Effect of turning body induced by acetic acid in mice (x ± s, n = 10).
| Group | Dosage |
潜
伏
期
|
扭
体
次
数
|
|---|---|---|---|
| NS | 2.8 ± 0.9 | 43.5 ± 13.8 | |
| EOZ low-dose | 20 mg | 3.0 ± 1.6③ | 40.7 ± 15.3③ |
| EOZ middle-dose | 40 mg | 3.6 ± 1.8③ | 29.5 ± 5.6② |
| EOZ high-dose | 80 mg | 4.2 ± 1.7① | 18.6 ± 6.4② |
| Ver | 5 mg | 3.9 ± 2.0③ | 19.6 ± 5.2② |
| EOZ + Ver low-dose | 20 mg + 5 mg | 4.3 ± 2.2① | 19.2 ± 5.5②④ |
| EOZ + Ver middle-dose | 40 mg + 5 mg | 4.5 ± 2.8① | 18.3 ± 4.6②④ |
| EOZ + Ver high-dose | 80 mg + 5 mg | 5.1 ± 3.1① | 16.1 ± 4.8②④ |
| Asp | 200 mg | 3.7 ± 1.3① | 18.6 ± 5.5② |
Values are presented as the mean ± S.E.M. (n = 10).
Compared with NS group: ①: P < 0.05, ②: P < 0.01, ③: P > 0.05; compared with relevant EOZ group: ④: P < 0.01.
Analegsia effect of the pain induced by hot-plate in mice (x ± s, n = 10).
| Group | Dosage (mg/kg) | Pain threshold of preadmin/s | Pain threshold of proadmin/s | ||||
|---|---|---|---|---|---|---|---|
| 15 min | 30 min | 60 min | 90 min | 120 min | |||
| NS | 19.6 ± 5.8 | 19.3 ± 5.5 | 19.9 ± 5.3 | 20.3 ± 5.1 | 20.5 ± 5.5 | 19.8 ± 5.4 | |
| EOZ low-dose | 20 mg | 19.8 ± 4.7 | 20.5 ± 5.8③ | 20.9 ± 6.1③ | 20.8 ± 5.8③ | 20.8 ± 6.2③ | 20.5 ± 5.6③ |
| EOZ middle-dose | 40 mg | 19.7 ± 4.8 | 23.9 ± 6.5③ | 31.4 ± 6.3① | 32.2 ± 7.1① | 34.8 ± 7.2① | 34.6 ± 6.9① |
| EOZ high-dose | 80 mg | 19.7 ± 5.3 | 24.5 ± 5.6③ | 35.2 ± 5.3② | 37.5 ± 6.1② | 38.1 ± 5.6② | 37.8 ± 5.3② |
| Ver | 5 mg | 20.3 ± 3.2 | 20.6 ± 5.2③ | 20.9 ± 6.1③ | 19.8 ± 6.4 | 21.5 ± 6.2③ | 21.6 ± 6.6③ |
| EOZ + Ver low-dose | 20 mg + 5 mg | 20.5 ± 4.1 | 25.8 ± 6.6③ | 32.2 ± 5.7②④ | 33.5 ± 5.2②④ | 34.8 ± 5.9②④ | 35.5 ± 6.2②④ |
| EOZ + Ver middle-dose | 40 mg + 5 mg | 19.6 ± 5.1 | 25.4 ± 5.2③ | 37.4 ± 5.3②④ | 40.6 ± 6.1②④ | 40.7 ± 6.1②④ | 41.5 ± 7.0②④ |
| EOZ + Ver high-dose | 80 mg + 5 mg | 19.8 ± 4.8 | 26.2 ± 8.2③ | 41.2 ± 6.8②④ | 45.2 ± 6.8②④ | 46.7 ± 6.5②④ | 45.8 ± 7.2②④ |
| Mor | 10 mg | 19.8 ± 4.6 | 45.3 ± 6.7② | 46.8 ± 7.2② | 45.3 ± 7.1② | 24.9 ± 5.6③ | 21.7 ± 4.9③ |
Compared with NS group: ①: P < 0.05, ②: P < 0.01, ③: P > 0.05; compared with relevant EOZ group: ④: P < 0.01.
Effect of the tail-curling latencies of mice in the warm water tail-flick test (x ± s, n = 10).
| Group | Dosage (mg/kg) | Basal TFL/s | TFL of proadmin/s | ||||
|---|---|---|---|---|---|---|---|
| 15 min | 30 min | 60 min | 90 min | 120 min | |||
| NS | 3.42 ± 0.52 | 3.48 ± 0.61 | 3.51 ± 0.72 | 3.62 ± 0.89 | 3.46 ± 0.61 | 3.48 ± 0.63 | |
| EOZ low-dose | 20 mg | 3.52 ± 0.68 | 3.72 ± 0.79③ | 4.16 ± 0.97③ | 4.25 ± 0.92③ | 4.20 ± 0.91③ | 4.25 ± 0.92③ |
| EOZ middle-dose | 40 mg | 3.45 ± 0.62 | 4.15 ± 0.67③ | 4.85 ± 0.78① | 5.01 ± 0.88① | 5.12 ± 0.75① | 5.12 ± 0.85① |
| EOZ high-dose | 80 mg | 3.50 ± 0.58 | 4.14 ± 0.85③ | 5.23 ± 0.82② | 5.41 ± 0.76② | 5.42 ± 0.83② | 5.41 ± 0.86② |
| Ver | 5 mg | 3.49 ± 0.78 | 3.50 ± 0.75③ | 3.51 ± 0.82③ | 3.41 ± 0.84③ | 3.54 ± 8.6③ | 3.48 ± 0.85③ |
| EOZ + Ver low-dose | 20 mg + 5 mg | 3.38 ± 0.72 | 4.56 ± 0.76③ | 6.85 ± 0.78②④ | 7.22 ± 0.75②④ | 7.34 ± 0.85②④ | 6.46 ± 0.78②④ |
| EOZ + Ver middle-dose | 40 mg + 5 mg | 3.32 ± 0.65 | 4.12 ± 0.78③ | 9.23 ± 0.66②④ | 9.54 ± 0.78②④ | 9.68 ± 0.82②④ | 9.57 ± 0.65②④ |
| EOZ + Ver high-dose | 80 mg + 5 mg | 3.47 ± 0.60 | 4.11 ± 0.73③ | 11.2 ± 0.78②④ | 12.4 ± 0.85②④ | 13.1 ± 0.87②④ | 12.5 ± 0.91②④ |
| Mor | 10 mg | 3.56 ± 0.63 | 13.68 ± 0.86② | 12.62 ± 0.76② | 11.42 ± 0.79② | 8.49 ± 0.88② | 5.52 ± 0.82② |
Compared with NS group: ①: P < 0.05, ②: P < 0.01, ③: P > 0.05; compared with EOZ group: ④: P < 0.05.
Effect of amplitude of action potential (AP) of sciatic nerve in toads (x ± s, n = 5).
| Group | Dosage (g/mL) | Preadmin/mV | Proadmin/mV | Time of AP | ||
|---|---|---|---|---|---|---|
| 1 min | 5 min | 10 min | min | |||
| RS | 4.35 ± 1.25 | 4.26 ± 1.32 | 4.30 ± 1.16 | 4.33 ± 1.53 | exist | |
| EOZ | 0.2% | 4.39 ± 1.43 | 3.21 ± 0.85①③ | 0 | 0 | 4.98 ± 0.92③ |
| Ver | 0.05% | 4.42 ± 1.02 | 4.39 ± 1.32 | 4.43 ± 1.06 | 4.29 ± 1.34 | exist |
| EOZ + Ver | 0.2% + 0.05% | 4.45 ± 1.03 | 2.36 ± 1.02②③ | 0 | 0 | 2.62 ± 0.58③⑤ |
| Lid | 1% | 4.53 ± 1.12 | 4.52 ± 1.35 | 4.50 ± 1.65①③ | 4.38 ± 1.65①③ | 22.89 ± 6.52③ |
Compared with preadministration: ①: P < 0.05, ②: P < 0.01; compared with NS group: ③: P < 0.05, ④: P < 0.01; compared with EOZ group: ⑤: P < 0.05.